The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated dose escalation results for ReFocus, a first-in-human study of highly selective FGFR2 inhibitor RLY-4008 in cholangiocarcinoma and other solid tumors.
 
Mitesh J. Borad
Stock and Other Ownership Interests - AVEO; Gilead Sciences; Intercept Pharmaceuticals; Spectrum Pharmaceuticals
Consulting or Advisory Role - Agios (Inst); ArQule (Inst); Celgene (Inst); De Novo Pharmaceuticals; Exelixis; Fujifilm (Inst); G1 Therapeutics; Genentech; Halozyme (Inst); Immunovative Therapies; Imvax; Inspyr Therapeutics; Insys Therapeutics (Inst); Klus Pharma; Lynx Group; Merck; Novartis (Inst); Pieris Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Western Oncolytics
Research Funding - Adaptimmune (Inst); Agios (Inst); ARIAD (Inst); AstraZeneca (Inst); Basilea (Inst); BiolineRx (Inst); Boston Biomedical (Inst); Celgene (Inst); Dicerna (Inst); Eisai (Inst); EMD Serono (Inst); Halozyme (Inst); ImClone Systems (Inst); Incyte (Inst); Incyte (Inst); Isis Pharmaceuticals (Inst); MedImmune (Inst); Merck Serono (Inst); miRNA Therapeutics (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); RedHill Biopharma (Inst); Senhwa Biosciences (Inst); Sillajen (Inst); Sun Biopharma (Inst); Taiho Pharmaceutical (Inst); Threshold Pharmaceuticals (Inst); Toray Industries (Inst); ZielBio (Inst)
Travel, Accommodations, Expenses - ArQule; AstraZeneca; Celgene
 
Alison M. Schram
Consulting or Advisory Role - Mersana; Merus NV; Relay Therapeutics
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Black Diamond Therapeutics (Inst); Elevation Oncology (Inst); Kura Oncology (Inst); Lilly (Inst); Merus (Inst); Pfizer (Inst); PMV Pharma (Inst); Relay Therapeutics (Inst); Repare Therapeutics (Inst); Revolution Medicines (Inst); Surface Oncology (Inst)
 
Richard D. Kim
Consulting or Advisory Role - Bayer; Exelixis; Lilly; Pfizer; QED Therapeutics; Roche/Genentech; SERVIER; Taiho Oncology
Speakers' Bureau - Eisai; Exelixis; Incyte
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst)
 
Suneel Deepak Kamath
Consulting or Advisory Role - Exelixis; Guardant Health; OncLive; Seagen; Tempus
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Foundation Medicine; Guardant Health; Ipsen; Janssen; Merck
 
Vaibhav Sahai
Consulting or Advisory Role - AstraZeneca; Autem Medical; GlaxoSmithKline; Histosonics; Incyte; Ipsen; QED Therapeutics; Rafael Pharmaceuticals; SERVIER
Research Funding - Actuate Therapeutics (Inst); Agios (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); Exelixis (Inst); FibroGen (Inst); Incyte (Inst); Ipsen (Inst); MedImmune (Inst); Pancreatic Cancer Action Network (Inst); Rafael Pharmaceuticals (Inst); Relay Therapeutics (Inst); Syros Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - ASCO; Lynx Group
 
Efrat Dotan
Honoraria - Pfizer
Consulting or Advisory Role - G1 Therapeutics; Helsinn Therapeutics; Incyte; Taiho Pharmaceutical
Research Funding - Gilead Sciences (Inst); Incyte (Inst); Ipsen (Inst); Kinnate Biopharma (Inst); Lilly (Inst); Lutris (Inst); NGM Biopharmaceuticals (Inst); Relay Therapeutics (Inst); Theradex (Inst); Zymeworks (Inst)
 
Robin Kate Kelley
Consulting or Advisory Role - Agios (Inst); AstraZeneca (Inst); Compass Therapeutics; Exelixis/Ipsen (Inst); Kinnate Biopharma; Merck (Inst); Regeneron; Tyra Biosciences
Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Exelixis (Inst); Genentech/Roche (Inst); Lilly (Inst); Loxo/Lilly (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Partner Therapeutics (Inst); QED Therapeutics (Inst); Relay Therapeutics (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Mariano Ponz-Sarvise
Consulting or Advisory Role - AstraZeneca Spain
Travel, Accommodations, Expenses - AstraZeneca (Inst); Incyte; Oncosil
 
Do-Youn Oh
Consulting or Advisory Role - Arcus Biosciences; ASLAN Pharmaceuticals; AstraZeneca; Basilea; Bayer; BeiGene; Celgene; Genentech/Roche; Halozyme; IQVIA; Merck Serono; Novartis; Taiho Pharmaceutical; Turning Point Therapeutics; Yuhan; Zymeworks
Research Funding - Array BioPharma; AstraZeneca; BeiGene; Handok; Lilly; MSD; Novartis; SERVIER
 
Jeffrey Yachnin
No Relationships to Disclose
 
Vaia Florou
Consulting or Advisory Role - Deciphera; Incyte
 
Philippe Alexandre Cassier
Honoraria - Amgen
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Janssen Oncology; OSE Immunotherapeutics
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Innate Pharma (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Taiho Pharmaceutical (Inst); Toray Industries (Inst); Transgene (Inst)
Travel, Accommodations, Expenses - Novartis; OSE Immunotherapeutics; Roche
 
Joon Oh Park
Consulting or Advisory Role - ABL Bio; Adicet Bio; AstraZeneca; Celgene; ImmuneOncia; Intocell; MediRama; Merck Serono; SERVIER
Research Funding - ABL Bio; Celgene; Eutilex; medpacto; SERVIER
Travel, Accommodations, Expenses - Minneamrita Therapeutics
 
Chih-Yi Liao
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Exelixis; Genentech; Histosonics; Incyte; Ipsen; Lexicon; Lilly; QED Therapeutics; TransThera Biosciences
Speakers' Bureau - AstraZeneca; Eisai; Exelixis; Incyte
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - AstraZeneca; Eisai; Exelixis; Incyte; Ipsen
 
Michael Millward
Consulting or Advisory Role - Amgen; AstraZeneca; BeiGene; Bristol-Myers Squibb; Guardant Health; IQvia; Lilly; Merck Serono; Novartis; Pfizer; Roche; The Limbic
Research Funding - Abbvie (Inst); Akeso Biopharma (Inst); Albion Laboratories (Inst); Alpine Immune Sciences (Inst); Amgen (Inst); Apollomics (Inst); AstraZeneca (Inst); AtriCure (Inst); Axelia Oncology (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); CStone Pharmaceuticals (Inst); Cullinan Oncology (Inst); Dizal Pharma (Inst); Eucure Biopharma (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Genfleet Therapeutics (Inst); GlaxoSmithKline (Inst); IMPAC Medical Systems (Inst); InventisBio (Inst); InxMed (Inst); Kinnate Biopharma (Inst); Lilly (Inst); Maxinovel (Inst); Relay Therapeutics (Inst); Turning Point Therapeutics (Inst); Tyra Biosciences (Inst); Vivace Therapeutics (Inst)
 
Florence (Tianhui) Ramirez
Employment - Relay Therapeutics
Stock and Other Ownership Interests - Relay Therapeutics
 
Fabien Jean Ricard
Employment - Relay Therapeutics
Stock and Other Ownership Interests - Relay Therapeutics
 
Antoine Hollebecque
Honoraria - Amgen; Eisai; Incyte; Relay Therapeutics; SERVIER
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune (Inst); Debiopharm Group (Inst); Gritstone Bio; Incyte (Inst); Lilly (Inst); QED therapeutics; Relay Therapeutics; Spectrum Pharmaceuticals (Inst); Taiho Oncology
Research Funding - AstraZeneca/MedImmune (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca/MedImmune; Incyte; Lilly; Roche; SERVIER
Other Relationship - Abbvie; Agios; Amgen; argenx; Arno Therapeutics; Astex Pharmaceuticals; AstraZeneca; AVEO; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Clovis Oncology; Daiichi Sankyo; Debiopharm Group; Eisai; Exelixis; FORMA Therapeutics; GamaMabs Pharma; Genentech; GlaxoSmithKline; H3 Biomedicine; Innate Pharma; Janssen-Cilag; Kyowa Hakko Kirin; Lilly; Loxo; Lytix Biopharma; MedImmune; Menarini; Merck Sharp & Dohme; Merrimack; Merus; Millenium Pharamceuticals; Nanobiotix; Nektar; Novartis; Octimet; Oncoethix; Onyx; Orion; Oryzon Genomics; Pfizer; Pierre Fabre; Roche; Roche/Genentech; Sanofi/Aventis; SERVIER; Taiho Pharmaceutical; Tesaro; Xencor
 
Vivek Subbiah
Consulting or Advisory Role - Helsinn Therapeutics; Loxo/Lilly; MedImmune; Pfizer; Relay Therapeutics
Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Exelixis (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); Inhibrx (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Relay Therapeutics (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst)
Travel, Accommodations, Expenses - Bayer; Foundation Medicine; Helsinn Therapeutics; Novartis; PharmaMar
Other Relationship - Medscape
 
Lipika Goyal
Consulting or Advisory Role - Alentis Therapeutics; AstraZeneca; Black Diamond Therapeutics; Blueprint Medicines; Compass Therapeutics; Eisai/H3 Biomedicine; Exelixis; Genentech; Incyte; Kinnate Biopharma; Merck; QED Therapeutics; SERVIER; Sirtex Medical; Synthekine; Taiho Pharmaceutical; TransThera Biosciences; Tyra Biosciences
(OPTIONAL) Uncompensated Relationships - Agios; Boehringer Ingelheim; Boehringer Ingelheim; Debiopharm Group; Merck; Taiho Pharmaceutical